TWi Pharmaceuticals, Inc.
4F, No. 41, Lane 221
Kang Chien Rd.
Nei Hu Dist.
Taipei
114
Tel: 886-2-26573350
Fax: 886-2-26573391
Website: http://www.twipharma.com/
Email: info@twipharma.com
26 articles about TWi Pharmaceuticals, Inc.
-
TWi Pharmaceuticals, Inc. Receives Favorable Decision From The U.S. Court Of Appeals For The Federal Circuit Regarding TWi's Generic Version Of MEGACE ES 625mg/5ml
12/16/2015
-
TWi Pharmaceuticals, Inc. Issues GDR And Raised NT$ 2.83 Billion
9/17/2015
-
TWi Pharmaceuticals, Inc. President & CEO Ms. Tina Guilder Will Resign From Her Current Roles And Chairman Dr. Chih-Ming Chen Will Become Interim President & CEO, Leading The Company In Its Continued Efforts To Develop High-Entry-Barrier Generics For The
8/31/2015
-
TWi Pharmaceuticals, Inc. Announces 2Q 2015 Financial Results And EPS For 2Q Of NT$0.69
8/14/2015
-
TWi Pharmaceuticals, Inc. Release: Twi Biotechnology Receives Notice Of Patent Allowance For Its Lead Drug Candidate AC-201 For The Indication Of Type II Diabetes In Europe And Russia
8/3/2015
-
TWi Pharmaceuticals, Inc. Launches Generic MEGACE ES After Favorable Decision In Patent Suit
7/29/2015
-
TWi Pharmaceuticals, Inc. Receives U.S. FDA Final Approval On Generic Guanfacine HCl ER Tablet
6/3/2015
-
TWi Pharmaceuticals, Inc. Announced The Promotion Of R&D EVP Jianbo Xie As COO
5/14/2015
-
TWi Pharmaceuticals, Inc. Announces Settlement With Takeda On Dexilant(R) Litigation
4/27/2015
-
TWi Pharmaceuticals, Inc. USA Announces The Receipt Of State Sales Licenses From All 50 States In The U.S.
4/17/2015
-
TWi Pharmaceuticals, Inc. Announces The First Shipment Of Its Generic Product In The U.S. Market
3/17/2015
-
TWi Pharmaceuticals, Inc. Receives Rare Disease Drug Designation For Its Drug Candidate AC-203 In Taiwan
3/10/2015
-
TWi Pharmaceuticals, Inc. Announces That Its Board Has Appointed Ms. Tina Guilder As The President & CEO And Ms. Eva Ho As CFO To Enhance The Strategic Move To Commercialize Its Products In The U.S. Market.
3/5/2015
-
TWi Pharmaceuticals, Inc. Announces That It Will Sell Its Products In The U.S. Market, Originally Planned To Be Sold By Teva, Through Its Wholly-Owned Subsidiary, TWi Pharmaceuticals USA
2/24/2015
-
Supernus Pharmaceuticals Sues TWi Pharmaceuticals, Inc. For Infringement Of Oxtellar XR® Patents
1/22/2015
-
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan
12/12/2014
-
TWi Pharmaceuticals, Inc. Receives U.S. FDA Approval On Generic Donepezil Hydrochloride Tablets USP, 23 Mg, Its Fifth ANDA From U.S. FDA
10/30/2014
-
TWi Pharmaceuticals, Inc. Receives FDA Final Approval On Generic Megestrol Acetate 125mg/Ml Oral Suspension
8/28/2014
-
TWi Pharmaceuticals, Inc. Announces Settlement Of Lidoderm® Patent Litigation
4/23/2014
-
TWi Pharmaceuticals, Inc.i Announces ANDA Approval Of Generic Procardia Xl® Tablets 30 Mg, 60 Mg And 90 Mg In The United States
4/7/2014